Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Everest Medicines Licenses DMX-200 from Dimerix – CCR2 Inhibitor for FSGS Targets Asia-Pacific Markets

Fineline Cube Jun 16, 2026
Company Deals

Harbour BioMed and BioMap Launch MegaStream TechBio – Next-Generation AI Drug Discovery Company Targeting Global Markets

Fineline Cube Jun 16, 2026
Company Deals

AstraZeneca Joins ZERO Prostate Cancer’s Blitz the Barriers Initiative – Ambitious Program Aims to Save 100,000 Lives by 2035

Fineline Cube Jun 16, 2026
Company Deals

Johnson & Johnson Invests $1 Billion in Jacksonville Vision Facility – Expands ACUVUE Manufacturing and Distribution

Fineline Cube Jun 16, 2026
Company Deals

Lynk Pharmaceuticals Files for Hong Kong IPO – Autoimmune Pipeline Led by JAK Inhibitors and Novel Protein Degraders

Fineline Cube Jun 16, 2026
Policy / Regulatory

China’s NHSA Receives Record 818 Drug Applications for 2026 National Reimbursement Drug List Adjustment

Fineline Cube Jun 15, 2026
Company Drug

Zelgen Biopharmaceuticals Secures NMPA Approval for Zepuping in Severe Alopecia Areata – First Immuno-Inflammatory Indication for Pan-JAK Inhibitor

Fineline Cube Jun 16, 2026
Company Drug

Hinova Pharmaceuticals Reports Positive Phase IIa Data for HP515 in MASH – THR-β Agonist Achieves >50% Liver Fat Reduction

Fineline Cube Jun 16, 2026
Company Drug

Sichuan Kelun Pharmaceutical to Present Clinical Data on RET Inhibitor and ADC at ASCO

Fineline Cube May 26, 2023

Sichuan Kelun Pharmaceutical Co., Ltd (SHE: 002422), a China-based pharmaceutical company, has unveiled plans to...

Policy / Regulatory R&D

Lancet Study Reveals Dalian’s Cancer Survival Rates Compared to US

Fineline Cube May 25, 2023

A recent study published in The Lancet has conducted a comparative analysis of cancer mortality...

Company Drug

BioRay Pharmaceutical’s LIV-1 Targeted ADC BRY812 Files IND in China

Fineline Cube May 25, 2023

Shanghai-based BioRay Pharmaceutical Co., Ltd has announced that an investigational new drug (IND) filing has...

Company Drug

Accropeutics Receives HREC Approval for AC-201 Phase I Trial

Fineline Cube May 25, 2023

Suzhou-based Accro Bioscience (Suzhou) Limited (Accropeutics) has announced that it has received approval from the...

Company Drug

Vcanbio Initiates Phase II Clinical Study for Dental Pulp Stem Cell Injection in Periodontitis

Fineline Cube May 25, 2023

China-based Vcanbio Cell & Gene Engineering Corp., Ltd (SHA: 600645) has announced the imminent initiation...

Company Drug

Mabwell Bioscience’s 9MW3811 Receives NMPA Approval for Clinical Trials in Oncology and Fibrosis

Fineline Cube May 25, 2023

China-based Mabwell (Shanghai) Bioscience Co., Ltd (SHA: 688062) has announced that it has received clinical...

Company Drug

Roche’s Rozlytrek on Track for Priority Review for Pediatric NTRK Fusion Tumor Treatment

Fineline Cube May 25, 2023

The Center for Drug Evaluation (CDE) website has indicated that Roche’s (SWX: ROG) Rozlytrek (entrectinib)...

Company Deals

Zelixir Biotech Secures Over RMB 100 Million in Series A Financing for Synthetic Biology Pipeline

Fineline Cube May 25, 2023

Shanghai-based Zelixir Biotech, a leading provider of protein structure prediction and design services, has reportedly...

Company Deals

PathoAI Secures Tens of Millions in Angel Financing for AI-Powered Pathology Solutions

Fineline Cube May 25, 2023

PathoAI, a company at the forefront of intelligent pathology and examination through artificial intelligence (AI),...

Company Drug

Asieris Pharmaceuticals to Present Phase I Results of APL-1202 Combo at ASCO

Fineline Cube May 25, 2023

China-based urogenital cancer specialist Asieris Pharmaceuticals (SHA: 688176) has announced that it will publish the...

Company Deals

MicroPort Endovascular MedTech Announces Private Placement to Fund Innovation and Expansion

Fineline Cube May 25, 2023

China-based Shanghai MicroPort Endovascular MedTech Co., Ltd (SHA: 688016) has announced plans to raise up...

Company Drug

Antengene’s ATG-022 Earns FDA Orphan Drug Designations for Gastric and Pancreatic Cancers

Fineline Cube May 24, 2023

China-based Antengene Corporation Limited (HKG: 6996) has announced that its in-house discovered and developed antibody...

Policy / Regulatory

CDE Drafts Proposal on Generic Drug Studies for Varieties without Reference Preparations

Fineline Cube May 24, 2023

The Center for Drug Evaluation (CDE) has released a Notice on the “Generic Study for...

Company Deals Digital

Mural Health Partners with Clinflash to Enhance Patient Payments in Clinical Trials

Fineline Cube May 24, 2023

US-based Mural Health has announced a strategic partnership with China-based Clinflash, both companies specializing in...

Company Drug

Hanx Biopharmaceuticals’ HX009 Receives US IND Approval for Lymphoma Treatment

Fineline Cube May 24, 2023

Wuhan-based firm Hanx Biopharmaceuticals Inc. has announced the receipt of an Investigational New Drug (IND)...

Company Deals Drug

Clover Biopharmaceuticals Partners with Kyuan Trade for Commercial Launch of AdimFlu-S (QIS) in China

Fineline Cube May 24, 2023

China-based Clover Biopharmaceuticals Ltd (Clover; HKG: 2197) has announced the establishment of a commercial partnership...

Company Drug

Minghui Pharmaceutical Initiates First-in-Human Trial for IGF-1R Antibody Fusion Protein MHB018A

Fineline Cube May 24, 2023

China-based Minghui Pharmaceutical Inc. has announced the commencement of a first-in-human Phase Ia trial for...

Company Deals

Shanghai Ark Biopharmaceutical Partners with WuXi STA for Commercial Supply of Ziresovir

Fineline Cube May 24, 2023

China’s Shanghai Ark Biopharmaceutical Co., Ltd. (ArkBio) has entered into a partnership with WuXi STA,...

Policy / Regulatory

China’s NMPA and NHC Tighten Regulations on Tramadol Compound Preparations

Fineline Cube May 24, 2023

The National Medical Products Administration (NMPA) and National Health Commission (NHC) have released a notification...

Company Drug

Sino Biopharmaceutical’s TQ-B3525 Files for Market Approval with CDE

Fineline Cube May 24, 2023

Sino Biopharmaceutical Ltd (HKG: 1177) has announced a market approval filing for its Category 1...

Posts pagination

1 … 540 541 542 … 684

Recent updates

  • Everest Medicines Licenses DMX-200 from Dimerix – CCR2 Inhibitor for FSGS Targets Asia-Pacific Markets
  • Zelgen Biopharmaceuticals Secures NMPA Approval for Zepuping in Severe Alopecia Areata – First Immuno-Inflammatory Indication for Pan-JAK Inhibitor
  • Hinova Pharmaceuticals Reports Positive Phase IIa Data for HP515 in MASH – THR-β Agonist Achieves >50% Liver Fat Reduction
  • Chia Tai Tianqing Presents Positive Phase II Data for TQC2938 in Allergic Rhinitis – Novel ST2-Targeting mAb Shows Efficacy Across Inflammatory Pathways
  • Harbour BioMed and BioMap Launch MegaStream TechBio – Next-Generation AI Drug Discovery Company Targeting Global Markets
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Everest Medicines Licenses DMX-200 from Dimerix – CCR2 Inhibitor for FSGS Targets Asia-Pacific Markets

Company Drug

Zelgen Biopharmaceuticals Secures NMPA Approval for Zepuping in Severe Alopecia Areata – First Immuno-Inflammatory Indication for Pan-JAK Inhibitor

Company Drug

Hinova Pharmaceuticals Reports Positive Phase IIa Data for HP515 in MASH – THR-β Agonist Achieves >50% Liver Fat Reduction

Company Drug

Chia Tai Tianqing Presents Positive Phase II Data for TQC2938 in Allergic Rhinitis – Novel ST2-Targeting mAb Shows Efficacy Across Inflammatory Pathways

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.